Skip to main
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is a promising company with a potential blockbuster drug, EB613, in development for postmenopausal osteoporosis, and other programs utilizing their N-Tab platform for oral peptide delivery. With a BUY rating and projected annual sales of $1.1Bn by 2040, Entera Bio's oral administration of drugs is seen as advantageous and may lead to better results. The company's experienced CEO is also involved in developing another oral tablet, EB618, for treating obesity, further demonstrating their expertise in the biotech industry.

Bears say

Entera Bio is still in the early stages of product development and may face challenges in obtaining FDA approval and gaining market acceptance. The company's current financial status is also a cause for concern, with significant losses reported in recent years. Additionally, the biopharmaceutical industry is highly competitive, and the success of ENTX's products will ultimately depend on their ability to differentiate themselves from other treatments in the market and gain market share.

ENTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ENTX has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.